 CAMBRIDGE, Mass., Dec. 17, 2020 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat Sath Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021. 